Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Opinion|Videos|July 2, 2025
Reshaping Rx: Navigating 2025 Drug Pricing Policies—Recording
Author(s)Laura Joszt, MA
Fact checked by: Maggie L. Shaw
In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.
Advertisement
Advertisement
During a conversation on the Trump administration’s 2025 drug pricing policies, panelists discussed the implications of the Most Favored Nation policy, the broader context of drug pricing reforms, and efforts to address pharmacy benefit manager (PBM) reform through greater transparency.
Related to this article
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Advertisement
Advertisement